Want to see ATNM full AI Analyst Report?
Top Page
Actinium Pharmaceuticals
(ATNM)
Select Model
Select Model
Rating:62Neutral
Price Target:
$1.50
▲(38.89% Upside)
Action:Reiterated
Date:10/23/26
ATNM scores in the low 60s primarily due to mixed fundamentals: improved TTM profitability and a low-leverage balance sheet are outweighed by continued heavy negative operating/free cash flow and very thin gross margin. Technicals are relatively strong with price above major moving averages and positive momentum, and valuation looks inexpensive based on the low P/E. Corporate updates are generally constructive, but exchange compliance/delisting risk remains a notable constraint.
Positive Factors
Clinical Pipeline Progress
Early safety, tumor uptake and retention, and ongoing dose escalation provide clinical validation for ATNM-400 and support broader development potential. If these findings persist, the program could diversify Actinium’s oncology pipeline beyond its established hematologic focus.
Negative Factors
Persistent Cash Burn
Deeply negative operating and free cash flow show that the business is not self-funding despite reported positive net income. Persistent cash burn can require additional financing to sustain trials, creating ongoing capital needs and potentially constraining development choices.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Pipeline Progress
Early safety, tumor uptake and retention, and ongoing dose escalation provide clinical validation for ATNM-400 and support broader development potential. If these findings persist, the program could diversify Actinium’s oncology pipeline beyond its established hematologic focus.
Read all positive factors
Actinium Pharmaceuticals (ATNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$44.02M
Dividend YieldN/A
Average Volume (3M)196.80K
Price to Earnings (P/E)3.9
Beta (1Y)1.65
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.36
Shares Outstanding31,441,437
10 Day Avg. Volume357,440
30 Day Avg. Volume196,796
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.09
Enterprise Value/Revenue-0.11
Enterprise Value/Gross Profit-0.11
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.18
Revenue Forecast (FY)$35.00M
Actinium Pharmaceuticals Business Overview & Revenue Model
Company Description
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leadi...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Actinium Pharmaceuticals’ ability to generate recurring product revenue from commercial drug sales is null. The company’s economic model is primarily driven by (1) raising capital through equity and/o...
Actinium Pharmaceuticals Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.09M | 90.00K | 0.00 | 81.00K | 1.03M | 1.14M |
| Gross Profit | 35.48M | 90.00K | -811.00K | 81.00K | 1.03M | 620.00K |
| EBITDA | 12.18M | -33.07M | -37.43M | -48.03M | -32.32M | -24.25M |
| Net Income | 11.31M | -33.89M | -38.24M | -48.82M | -33.02M | -24.77M |
Balance Sheet | ||||||
| Total Assets | 40.16M | 51.77M | 76.90M | 81.44M | 114.19M | 80.39M |
| Cash, Cash Equivalents and Short-Term Investments | 36.47M | 48.00M | 72.90M | 76.68M | 108.91M | 77.83M |
| Total Debt | 1.34M | 1.69M | 1.57M | 2.11M | 2.58M | 310.00K |
| Total Liabilities | 9.86M | 43.94M | 44.14M | 45.07M | 47.71M | 6.84M |
| Stockholders Equity | 30.30M | 7.83M | 32.76M | 36.38M | 66.48M | 73.55M |
Cash Flow | ||||||
| Free Cash Flow | -23.25M | -24.68M | -33.08M | -47.49M | 8.28M | -21.00M |
| Operating Cash Flow | -22.66M | -24.58M | -33.07M | -47.34M | 8.64M | -20.87M |
| Investing Cash Flow | -584.00K | -104.00K | -11.00K | -153.00K | -366.00K | -133.00K |
| Financing Cash Flow | -217.00K | -217.00K | 29.32M | 14.87M | 23.11M | 35.22M |
Actinium Pharmaceuticals Technical Analysis
Positive
1.08
Price Trends
1.16
Positive
1.05
Positive
1.12
Positive
Market Momentum
0.08
Negative
59.65
Neutral
78.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Positive. The current price of 1.08 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.16, and below the 200-day MA of 1.12, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 59.65 is Neutral, neither overbought nor oversold. The STOCH value of 78.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATNM.
Actinium Pharmaceuticals Risk Analysis
Actinium Pharmaceuticals disclosed 68 risk factors in its most recent earnings report. Actinium Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Actinium Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $44.02M | 3.89 | 83.42% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $111.83M | -1.66 | -708.20% | ― | ― | 30.16% | |
48 Neutral | $11.44M | -0.27 | -165.71% | ― | ― | 77.68% | |
47 Neutral | $15.11M | -1.89 | -56.96% | ― | -56.64% | 64.88% | |
45 Neutral | $24.34M | -0.42 | 142.25% | ― | -58.14% | 47.25% | |
42 Neutral | $10.45M | -0.05 | -443.08% | ― | ― | 75.09% |
* Healthcare Sector Average
ATNM
Actinium Pharmaceuticals
1.40
-0.08
-5.41%
CLRB
Cellectar Biosciences
1.21
-2.10
-63.44%
PDSB
PDS Biotechnology
1.07
0.13
14.15%
GTBP
GT Biopharma
5.07
-11.60
-69.59%
MRKR
Marker Therapeutics
0.91
-0.10
-10.30%
CELU
Celularity
0.75
-1.25
-62.50%
Actinium Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Actinium Pharmaceuticals Appoints Matt David as Chief Financial Officer
Positive
Oct 15, 2026
On October 15, 2026, Actinium Pharmaceuticals announced the appointment of Matt David, M.D. as Chief Financial Officer, with responsibility for finance, accounting, capital markets and investor relations, and serving as principal financial officer...
Business Operations and StrategyDelistings and Listing ChangesProduct-Related AnnouncementsRegulatory Filings and Compliance
Actinium Pharmaceuticals Expands Actimab-A Patents, Manufacturing Capacity
Positive
Aug 14, 2026
On August 14, 2026, Actinium Pharmaceuticals announced significant progress in its Actimab-A program, reporting newly issued patents that broaden protection for its use in treating myeloid hematologic malignancies and extending its anti-CD33 platf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.